Please login or register first to view this content.
Endocrine Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Guidelines Updated for Hospitalized Adults With Hyperglycemia
May 2022: Notable Drug Approvals
ADA: Once-Weekly Dulaglutide Ups Glycemic Control in Youth With T2D
Dulaglutide Improves Glycemic Control in Youth With Uncontrolled T2D
ADA: Tirzepatide Improves Kidney Outcomes in T2DM With Increased CV Risk
Heart Failure Hospitalization Risk Compared With Empagliflozin vs Other Glucose-Lowering Txs
SGLT2 Inhibitors Shown to Increase Uric Acid Excretion
Updates Issued for Standards of Medical Care in Diabetes
Metformin, Lifestyle Changes Cut Risk for T2DM, But Not CVD
Eldecalcitol Does Not Prevent Type 2 Diabetes in At-Risk
Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D
Dasiglucagon Reduces Glucose Requirements in Congenital Hyperinsulinism Trial
Early Glycemic Control May Cut CV Risk in Type 2 Diabetes
Using New Guidelines Would Increase Diabetes Screening Eligibility
Labcorp Provides HbA1c Testing With At-Home Collection Kit
FDA Approves First-in-Class Treatment for Type 2 Diabetes
Effects of Intranasal Insulin on Cognition, Mobility Studied in Elderly
Once-Weekly Insulin Icodec Superior to Daily Insulin Degludec in Reducing HbA1c
